Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately-to-severely active rheumatoid arthritis and inadequate response to methotrexate (MTX-IR): summary results from the 52-week phase 3 RA-BEAM study

Autor: Taylor, Peter, Krogulec, Marek, Dudek, Anna, Dudler, Jean, Drescher, E, Cseuz, R, Kausiene, Rasa, Andersone, Daina, Unikiene, Dalia, Burson, Juan Sanchez, Alonso, Ricardo Blanco, Dvořák, Zdeněk, Petru Ghizdavescu, Andrei, Irto, Ildiko, Larsson, Esbjörn, Bello, Natalia, Barry, Jane, Durand, Frederick, Holzkämper, Thorsten, Otawa, Susan, de Bono, Stephanie, Keystone, Edward, Rubbert-Roth, Andrea, Combe, Bernard, de la Torre, Inmaculada

Publikováno v: 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20170906-20170909; Stuttgart; DOCRA.03 /20170904/

Background: Baricitinib, an oral JAK1/JAK2 inhibitor, has shown promising results in patients with active rheumatoid arthritis (RA). We present efficacy and safety results from the phase 3 RA-BEAM study in patients with active RA and inadequate respo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26473620ce6eaff1149f5ca201231849
http://www.egms.de/en/meetings/dgrh2017/17dgrh156.shtml